Fosun Pharma: Controlled subsidiary's drug granted clinical trial approval.

Fosun Pharma announced that its holding subsidiary, Shanghai Henlius Biotech, and its holding subsidiary have received approval from the National Medical Products Administration to conduct Phase I/II clinical trials for the treatment of advanced colorectal cancer with HLX701 in combination with cetuximab and chemotherapy. Henlius plans to conduct relevant clinical trials of the drug in China after meeting the necessary requirements.